Use of cytoprotective agents in the treatment of gastric ulcers.
D000535:Aluminum / Q000009:adverse effects / Q000627:therapeutic use; D001729:Bismuth / Q000009:adverse effects / Q000627:therapeutic use; D002229:Carbenoxolone / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000188:drug therapy; D006801:Humans; D009942:Organometallic Compounds; D010919:Placebos; D011453:Prostaglandins / Q000627:therapeutic use; D013276:Stomach Ulcer / Q000188:drug therapy*; D013392:Sucralfate
D009942:Organometallic Compounds; D010919:Placebos; D011453:Prostaglandins; D013392:Sucralfate; D000535:Aluminum; C002791:bismuth tripotassium dicitrate; D002229:Carbenoxolone; D001729:Bismuth